Healthcare / Pharmaceutical RetailersMilan
$0.41
-0.00 (-0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-3.4M · quality 57.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
63.3x
↑ROE
-81.3%
↓Gross Margin
26.7%
↓Debt/Equity
1.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.4%
FCF CAGR
—
FCF margin
-3.9%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $55.7M · net income $-4.4M · FCF $-2.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $55.7M | $55.7M | $63.4M | $71.6M | $65.8M |
| Net Income | $-4.4M | $-4.4M | $-3.0M | $-3.2M | $-1.3M |
| EBITDA | $352604.00 | $352604.00 | $728272.00 | $-405577.00 | $-72571.00 |
| EPS | — | — | -0.08 | -0.08 | -0.04 |
| Gross Margin | 26.7% | 26.7% | 26.4% | 22.3% | 15.5% |
| Operating Margin | -9.8% | -9.8% | -3.2% | -4.2% | -2.3% |
| Net Margin | -8.0% | -8.0% | -4.7% | -4.5% | -2.0% |
| Balance Sheet | |||||
| Debt/Equity | 1.39 | 1.39 | 0.69 | — | 0.11 |
| Current Ratio | 0.92 | 0.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.2M | $-2.2M | $-3.4M | $-7.1M | — |
| Returns | |||||
| ROE | -81.3% | -81.3% | -28.1% | -25.0% | -7.7% |
| Valuation | |||||
| EV/EBITDA | 63.32 | 63.32 | 41.06 | — | — |
| P/B | 2.88 | 2.88 | 2.43 | 2.63 | 4.41 |
| Growth & Yield | |||||
| Revenue Growth | -12.2% | -12.2% | -11.4% | 8.7% | — |
| EPS Growth | — | — | 8.0% | -133.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.08 → n/d
Residual
-32.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.